Total number of shares and voting rights in Zealand Pharma at November 30, 2021
Zealand Pharma announced the total number of shares and voting rights as of November 30, 2021. Following an increase in share capital due to employee warrant exercises, the total shares stood at 43,628,742, reflecting an equal number of voting rights. The company remains focused on innovative peptide-based medicines, with more than 10 drug candidates in clinical development, including two already on the market. Zealand Pharma has strategic collaborations with major firms like Boehringer Ingelheim and AstraZeneca.
- Total shares and voting rights increased to 43,628,742, enhancing liquidity.
- Over 10 drug candidates in clinical development, indicating strong pipeline.
- Strategic collaborations with Boehringer Ingelheim and AstraZeneca for wider market opportunities.
- None.
Company announcement – No. 72 / 2021
Total number of shares and voting rights in Zealand Pharma at November 30, 2021
Copenhagen, DK and Boston, MA, November 30, 2021 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, in accordance with section 32 of the Danish Capital Markets Act, announces the total number of shares and voting rights in the Company at the end of a calendar month during which there have been changes to its share capital.
In Company announcement No. 69/2021 from November 19, 2021, Zealand announced an increase in share capital relating to the exercise of employee warrants. Following this announcement, the table below lists the total number of shares and voting rights in Zealand up to and including November 30, 2021.
Date | Number of shares (nominal value of DKK 1 each) | Share capital (nominal value in DKK) | Number of voting rights |
| November 30, 2021 | 43,628,742 | 43,628,742 | 43,628,742 |
# # #
About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, development, and commercialization of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market. In addition, license collaborations with Boehringer Ingelheim and AstraZeneca create opportunity for more patients to potentially benefit from Zealand-invented peptide investigational agents currently in development.
Zealand was founded in 1998 in Copenhagen, Denmark, and has presence throughout the U.S. that includes key locations in Boston, and Marlborough (MA). For more information about Zealand’s business and activities, please visit http://www.zealandpharma.com.
Zegalogue® and V-Go® are registered trademarks of Zealand Pharma A/S.
Forward-Looking Statement
The above information contains forward-looking statements that provide Zealand Pharma’s expectations or forecasts of future events. Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions, which may cause actual results to differ materially from expectations set forth herein and may cause any or all of such forward-looking statements to be incorrect. If any or all of such forward-looking statements prove to be incorrect, our actual results could differ materially and adversely from those anticipated or implied by such statements. All such forward-looking statements speak only as of the date of this release and are based on information available to Zealand Pharma as of the date of this release.
For further information, please contact:
| Zealand Pharma Investor Relations |
| Maeve Conneighton |
| Argot Partners |
| investors@zealandpharma.com |
| Zealand Pharma Media Relations |
| David Rosen |
| Argot Partners |
| media@zealandpharma.com |
FAQ
What is the total number of shares of Zealand Pharma as of November 30, 2021?
What are the voting rights associated with Zealand Pharma's shares?
What is the significance of the employee warrant exercise announced by Zealand Pharma?
How many drug candidates does Zealand Pharma have in clinical development?
Which companies has Zealand Pharma collaborated with?
